114 related articles for article (PubMed ID: 8653684)
1. Novel germline p16 mutation in familial malignant melanoma in southern Sweden.
Borg A; Johannsson U; Johannsson O; Häkansson S; Westerdahl J; Mäsbäck A; Olsson H; Ingvar C
Cancer Res; 1996 Jun; 56(11):2497-500. PubMed ID: 8653684
[TBL] [Abstract][Full Text] [Related]
2. A single Mediterranean, possibly Jewish, origin for the Val59Gly CDKN2A mutation in four melanoma-prone families.
Yakobson E; Eisenberg S; Isacson R; Halle D; Levy-Lahad E; Catane R; Safro M; Sobolev V; Huot T; Peters G; Ruiz A; Malvehy J; Puig S; Chompret A; Avril MF; Shafir R; Peretz H; Bressac-de Paillerets B
Eur J Hum Genet; 2003 Apr; 11(4):288-96. PubMed ID: 12700603
[TBL] [Abstract][Full Text] [Related]
3. Analysis of the p16 gene, CDKN2, in 17 Australian melanoma kindreds.
Holland EA; Beaton SC; Becker TM; Grulet OM; Peters BA; Rizos H; Kefford RF; Mann GJ
Oncogene; 1995 Dec; 11(11):2289-94. PubMed ID: 8570179
[TBL] [Abstract][Full Text] [Related]
4. Molecular analysis of P16(Ink4)/CDKN2 and P15(INK4B)/MTS2 genes in primary human testicular germ cell tumors.
Heidenreich A; Gaddipati JP; Moul JW; Srivastava S
J Urol; 1998 May; 159(5):1725-30. PubMed ID: 9554401
[TBL] [Abstract][Full Text] [Related]
5. Germline p16INK4A mutation and protein dysfunction in a family with inherited melanoma.
Liu L; Lassam NJ; Slingerland JM; Bailey D; Cole D; Jenkins R; Hogg D
Oncogene; 1995 Jul; 11(2):405-12. PubMed ID: 7624155
[TBL] [Abstract][Full Text] [Related]
6. Analysis of the p16 gene (CDKN2) as a candidate for the chromosome 9p melanoma susceptibility locus.
Kamb A; Shattuck-Eidens D; Eeles R; Liu Q; Gruis NA; Ding W; Hussey C; Tran T; Miki Y; Weaver-Feldhaus J
Nat Genet; 1994 Sep; 8(1):23-6. PubMed ID: 7987388
[TBL] [Abstract][Full Text] [Related]
7. Germ-line deletion involving the INK4 locus in familial proneness to melanoma and nervous system tumors.
Bahuau M; Vidaud D; Jenkins RB; Bièche I; Kimmel DW; Assouline B; Smith JS; Alderete B; Cayuela JM; Harpey JP; Caille B; Vidaud M
Cancer Res; 1998 Jun; 58(11):2298-303. PubMed ID: 9622062
[TBL] [Abstract][Full Text] [Related]
8. Two p16 (CDKN2A) germline mutations in 30 Israeli melanoma families.
Yakobson E; Shemesh P; Azizi E; Winkler E; Lassam N; Hogg D; Brookes S; Peters G; Lotem M; Zlotogorski A; Landau M; Safro M; Shafir R; Friedman E; Peretz H
Eur J Hum Genet; 2000 Aug; 8(8):590-6. PubMed ID: 10951521
[TBL] [Abstract][Full Text] [Related]
9. Loss of the p16INK4a and p15INK4b genes, as well as neighboring 9p21 markers, in sporadic melanoma.
Flores JF; Walker GJ; Glendening JM; Haluska FG; Castresana JS; Rubio MP; Pastorfide GC; Boyer LA; Kao WH; Bulyk ML; Barnhill RL; Hayward NK; Housman DE; Fountain JW
Cancer Res; 1996 Nov; 56(21):5023-32. PubMed ID: 8895759
[TBL] [Abstract][Full Text] [Related]
10. Analysis of the CDKN2A, CDKN2B and CDK4 genes in 48 Australian melanoma kindreds.
Flores JF; Pollock PM; Walker GJ; Glendening JM; Lin AH; Palmer JM; Walters MK; Hayward NK; Fountain JW
Oncogene; 1997 Dec; 15(24):2999-3005. PubMed ID: 9416844
[TBL] [Abstract][Full Text] [Related]
11. Germline p16 mutations in familial melanoma.
Hussussian CJ; Struewing JP; Goldstein AM; Higgins PA; Ally DS; Sheahan MD; Clark WH; Tucker MA; Dracopoli NC
Nat Genet; 1994 Sep; 8(1):15-21. PubMed ID: 7987387
[TBL] [Abstract][Full Text] [Related]
12. Familial head and neck cancer: molecular analysis of a new clinical entity.
Yu KK; Zanation AM; Moss JR; Yarbrough WG
Laryngoscope; 2002 Sep; 112(9):1587-93. PubMed ID: 12352668
[TBL] [Abstract][Full Text] [Related]
13. Genetic and epigenetic alterations of the cyclin-dependent kinase inhibitors p15INK4b and p16INK4a in human thyroid carcinoma cell lines and primary thyroid carcinomas.
Elisei R; Shiohara M; Koeffler HP; Fagin JA
Cancer; 1998 Nov; 83(10):2185-93. PubMed ID: 9827724
[TBL] [Abstract][Full Text] [Related]
14. Affected members of melanoma-prone families with linkage to 9p21 but lacking mutations in CDKN2A do not harbor mutations in the coding regions of either CDKN2B or p19ARF.
Liu L; Goldstein AM; Tucker MA; Brill H; Gruis NA; Hogg D; Lassam NJ
Genes Chromosomes Cancer; 1997 May; 19(1):52-4. PubMed ID: 9135995
[TBL] [Abstract][Full Text] [Related]
15. Screening of germline mutations in the CDKN2A and CDKN2B genes in Swedish families with hereditary cutaneous melanoma.
Platz A; Hansson J; Månsson-Brahme E; Lagerlof B; Linder S; Lundqvist E; Sevigny P; Inganäs M; Ringborg U
J Natl Cancer Inst; 1997 May; 89(10):697-702. PubMed ID: 9168184
[TBL] [Abstract][Full Text] [Related]
16. Homozygotes for CDKN2 (p16) germline mutation in Dutch familial melanoma kindreds.
Gruis NA; van der Velden PA; Sandkuijl LA; Prins DE; Weaver-Feldhaus J; Kamb A; Bergman W; Frants RR
Nat Genet; 1995 Jul; 10(3):351-3. PubMed ID: 7670475
[TBL] [Abstract][Full Text] [Related]
17. Compilation of somatic mutations of the CDKN2 gene in human cancers: non-random distribution of base substitutions.
Pollock PM; Pearson JV; Hayward NK
Genes Chromosomes Cancer; 1996 Feb; 15(2):77-88. PubMed ID: 8834170
[TBL] [Abstract][Full Text] [Related]
18. Differential expression of p16INK4a and p16beta transcripts in B-lymphoblastoid cells from members of hereditary melanoma families without CDKN2A exon mutations.
Rizos H; Becker TM; Holland EA; Kefford RF; Mann GJ
Oncogene; 1997 Jul; 15(5):515-23. PubMed ID: 9247305
[TBL] [Abstract][Full Text] [Related]
19. Mutation testing in melanoma families: INK4A, CDK4 and INK4D.
Newton Bishop JA; Harland M; Bennett DC; Bataille V; Goldstein AM; Tucker MA; Ponder BA; Cuzick J; Selby P; Bishop DT
Br J Cancer; 1999 Apr; 80(1-2):295-300. PubMed ID: 10390011
[TBL] [Abstract][Full Text] [Related]
20. CDKN2A/p16 is inactivated in most melanoma cell lines.
Castellano M; Pollock PM; Walters MK; Sparrow LE; Down LM; Gabrielli BG; Parsons PG; Hayward NK
Cancer Res; 1997 Nov; 57(21):4868-75. PubMed ID: 9354451
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]